Plain-English translation of NCT00979745 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Liver disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial studied whether , a medication given as small under-the-skin implants, could protect people with erythropoietic protoporphyria (EPP) — a rare genetic disorder that causes severe, painful reactions to sunlight. The medication works by naturally increasing skin pigmentation (darkening), similar to how a tan protects skin, but without the DNA damage that comes from traditional sun exposure treatments. Researchers wanted to confirm whether this treatment was safe and effective at reducing the severity of these painful sun reactions.
People with EPP currently manage their condition by avoiding sunlight and using treatments like sun lamps, which unfortunately damage skin cells and increase skin cancer risk. This medication offers a potentially safer way to darken skin and provide natural sun protection without those dangerous side effects.
Participants were randomly assigned to receive either the active medication or a placebo implant. Over an 8-month period, they received five small implants placed under the skin (on days 0, 60, 120, 180, and 240). The implants slowly released the medication over time and were designed to be absorbed by the body naturally. Throughout the study, participants visited the clinic for check-ups and monitoring to track how well the treatment worked and to watch for any side effects.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Finland
France
Germany
Ireland
Netherlands